Inhibrx (INBX) to Release Earnings on Thursday

Inhibrx (NASDAQ:INBX - Get Free Report) is projected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Inhibrx to post earnings of ($2.88) per share for the quarter.

Inhibrx Trading Down 2.7 %

Shares of NASDAQ INBX traded down $0.35 during mid-day trading on Friday, hitting $12.60. 75,504 shares of the stock traded hands, compared to its average volume of 98,178. The stock has a fifty day moving average price of $14.24 and a 200-day moving average price of $14.61. Inhibrx has a 52 week low of $10.80 and a 52 week high of $18.95.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Insider Buying and Selling

In related news, Director Jon Faiz Kayyem bought 69,686 shares of the company's stock in a transaction on Tuesday, November 19th. The shares were acquired at an average cost of $14.23 per share, with a total value of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares of the company's stock, valued at $727,053.39. The trade was a -374.80 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.20% of the stock is currently owned by insiders.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.